Janux Therapeutics (JANX) Enterprise Value (2020 - 2026)

Janux Therapeutics (JANX) has 7 years of Enterprise Value data on file, last reported at -$956.4 million in Q1 2026.

• On a quarterly basis, Enterprise Value rose 5.7% year-over-year to -$956.4 million in Q1 2026; TTM through Mar 2026 was -$956.4 million, a 5.7% increase from a year earlier, with the FY2025 full-year figure at -$966.6 million, up 5.72% from the prior year.
• Enterprise Value for Q1 2026 stood at -$956.4 million, up from -$966.6 million in the prior quarter.
• Over the last five years, Enterprise Value for JANX reached as high as -$303.3 million in Q2 2023 and fell as low as -$1.0 billion in Q4 2024.
• Historically, Enterprise Value has averaged -$623.4 million across 5 years, with a median of -$646.3 million in 2024.
• Across the five-year window, Enterprise Value grew 14.4% in 2023 and slumped 197.99% in 2024, its largest moves.
• Year by year, Enterprise Value stood at -$327.0 million in 2022, then fell by 5.2% to -$344.0 million in 2023, then slumped by 197.99% to -$1.0 billion in 2024, then advanced by 5.72% to -$966.6 million in 2025, then advanced by 1.05% to -$956.4 million in 2026.
• Per Business Quant data, the three most recent Enterprise Value figures were -$956.4 million in Q1 2026, -$966.6 million in Q4 2025, and -$989.0 million in Q3 2025.